Soficitinib
Soficitinib (Compound 20) is a selective inhibitor targeting tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) with an IC50 values of 0.5 nM and 1.2 nM, respectively. Soficitinib is promising for research of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and inflammatory diseases[1].
Product Specifications
CAS Number
[2574524-67-5]
UNSPSC
12352005
Target
JAK
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Inflammation/Immunology
Smiles
C[C@]12[C@](CN(C2)C(CC#N)=O)([H])CN(C3=NC(NC4=CN(C)N=C4)=NC=C3Cl)C1
Molecular Formula
C18H21ClN8O
Molecular Weight
400.87
References & Citations
[1]Heterocyclic compound, preparation method and application thereof in medicine and pharmacology. CN112142743A. 2020-12-29.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-177131/
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
19,20-dihydroxy-4(Z),7(Z),10(Z),13(Z),16(Z)-docosapentaenoic acid
19,20-dihydroxy-4(Z),7(Z),10(Z),13(Z),16(Z)-docosapentaenoic acid